Therapeutic and Diagnostic Guidelines
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2021; 13(1): 1-11
Published online Jan 15, 2021. doi: 10.4251/wjgo.v13.i1.1
Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review
Maham Farshidpour, Monjur Ahmed, Shilpa Junna, Juanita L Merchant
Maham Farshidpour, Inpatient Medicine, Banner University of Medical Center, Tucson, AZ 85724, United States
Monjur Ahmed, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA 19107, United States
Shilpa Junna, Juanita L Merchant, Division of Gastroenterology and Hepatology, Banner University of Medical Center, Tucson, AZ 85724, United States
Author contributions: Farshidpour M and Merchant JL conceived of and designed the study, and collected the data; Farshidpour M, Ahmed M, Junna S, and Merchant JL drafted the manuscript; all authors reviewed the results and approved the final version of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maham Farshidpour, MD, Doctor, Inpatient Medicine, Banner University of Medical Center, 1501 N Campbell Ave, Tucson, AZ 85724, United States. mfarshidpour@email.arizona.edu
Received: August 25, 2020
Peer-review started: August 25, 2020
First decision: November 16, 2020
Revised: December 1, 2020
Accepted: December 16, 2020
Article in press: December 16, 2020
Published online: January 15, 2021
Core Tip

Core Tip: In patients with cancer, the levels of myeloid-derived suppressor cells (MDSCs) are presumed to be of prognostic and predictive value. Recent studies have shown that MDSCs appear to be independent prognostic factors in gastrointestinal cancer. In addition, therapeutics that target MDSCs have been shown to enhance anti-tumor immune responses in animal models. Consequently, a better understanding of the role and mechanism of action of MDSCs in the tumor microenvironment may aid in the development of novel immune-targeted therapies.